A Phase 3 interventional study of RSVPreF3 OA investigational vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 19 sites in 3 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-15.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 11th largest by enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 4th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2021.
This study's enrollment of 770 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 18th largest by enrollment, is one of 6 that started in 2021, is one of 21 in phase 3, and was the 22nd registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the lot-to-lot consistency in terms of immunogenicity and evaluate the safety and reactogenicity of 3 lots of the RSVPreF3 OA investigational vaccine administered as a single dose in adults ≥ 60 years of age (YOA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical conditions
Prior/Concomitant therapy
Prior/Concurrent clinical study experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 1 and AS01E adjuvant Lot A at Day 1 and were followed up until the study end (Month 6).
Biological: RSVPreF3 OA investigational vaccine
Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 2 and AS01E adjuvant Lot B at Day 1 and were followed up until the study end (Month 6).
Biological: RSVPreF3 OA investigational vaccine
Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 3 and AS01E adjuvant Lot C at Day 1 and were followed up until the study end (Month 6).
Biological: RSVPreF3 OA investigational vaccine
One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC)
Enzyme-linked immunosorbent assay (ELISA) was used to assess the concentrations of IgG antibodies against RSV PreF3 in serum samples.
Time frame: At 30 days post-vaccination (Day 31)
RSVPreF3 Specific IgG Antibody Concentrations Expressed as Mean Geometric Increase (MGI)
MGI was defined as the geometric mean of the within participant ratios of the post-vaccination RSV PreF3 IgG concentration over the pre-vaccination RSV PreF3 IgG concentration.
Time frame: At 30 days post-vaccination (Day 31)
Percentage of Participants Reporting Solicited Administration Site Events
Solicited administration site adverse events (AEs) assessed were erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade.
Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after study intervention administration
Percentage of Participants Reporting Solicited Systemic Events
Solicited systemic events assessed were arthralgia, fatigue, fever \[defined as temperature equal to or above (\>=) 38 degrees Celsius (°C)/100.4 degrees Fahrenheit (°F)}, headache and myalgia. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination.
Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after study intervention administration
Percentage of Participants Reporting at Least One Unsolicited Adverse Event
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Unsolicited AEs include serious, non-serious AEs and potential immune-mediated diseases (pIMDs).
Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after study intervention administration
Percentage of Participants Reporting at Least One Serious Adverse Event (SAE)
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.
Time frame: From Day 1 up to study end (6 months after vaccination)
Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD)
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From Day 1 up to study end (6 months after vaccination)
| Milestone | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| Started | 251 | 253 | 253 |
| Completed | 249 | 248 | 248 |
| Not completed | 2 | 5 | 5 |
| Withdrew: Adverse event | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 2 | 3 | 3 |
Enzyme-linked immunosorbent assay (ELISA) was used to assess the concentrations of IgG antibodies against RSV PreF3 in serum samples.
| ELISA Units/milliliter | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC) | 86039.9 (78541.5 to 94254.3) | 80518 (73150 to 88628.2) | 94260.9 (86042.2 to 103264.7) |
MGI was defined as the geometric mean of the within participant ratios of the post-vaccination RSV PreF3 IgG concentration over the pre-vaccination RSV PreF3 IgG concentration.
| Ratio | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| RSVPreF3 Specific IgG Antibody Concentrations Expressed as Mean Geometric Increase (MGI) | 11.84 (10.53 to 13.31) | 11.29 (10.12 to 12.6) | 12.46 (11.13 to 13.94) |
Solicited administration site adverse events (AEs) assessed were erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade.
| Percentage of participants | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| Erythema | 12.4 (8.6 to 17.2) | 11.6 (7.9 to 16.2) | 13.5 (9.5 to 18.3) |
| Pain | 58.2 (51.8 to 64.4) | 65.7 (59.5 to 71.6) | 62.7 (56.4 to 68.7) |
| Swelling | 6.8 (4 to 10.7) | 7.6 (4.6 to 11.6) | 7.9 (4.9 to 12) |
Solicited systemic events assessed were arthralgia, fatigue, fever \[defined as temperature equal to or above (\>=) 38 degrees Celsius (°C)/100.4 degrees Fahrenheit (°F)}, headache and myalgia. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination.
| Percentage of participants | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| Arthralgia | 13.3 (9.3 to 18.1) | 13.9 (9.9 to 18.9) | 14.7 (10.6 to 19.7) |
| Fatigue | 28.1 (22.6 to 34.1) | 25.9 (20.6 to 31.8) | 27.8 (22.3 to 33.7) |
| Fever | 2 (0.7 to 4.6) | 1.6 (0.4 to 4) | 2.8 (1.1 to 5.6) |
| Headache | 25.7 (20.4 to 31.6) | 23.5 (18.4 to 29.2) | 22.2 (17.2 to 27.9) |
| Myalgia | 31.3 (25.6 to 37.5) | 34.3 (28.4 to 40.5) | 33.7 (27.9 to 39.9) |
An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Unsolicited AEs include serious, non-serious AEs and potential immune-mediated diseases (pIMDs).
| Percentage of participants | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| Percentage of Participants Reporting at Least One Unsolicited Adverse Event | 14.7 (10.6 to 19.7) | 14.6 (10.5 to 19.6) | 13.4 (9.5 to 18.3) |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.
| Percentage of Participants | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| Percentage of Participants Reporting at Least One Serious Adverse Event (SAE) | 3.2 (1.4 to 6.2) | 2.4 (0.9 to 5.1) | 2.8 (1.1 to 5.6) |
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Percentage of participants | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD) | 0.8 (0.1 to 2.8) | 0.4 (0 to 2.2) | 1.2 (0.2 to 3.4) |
Collected over Solicited AEs were collected during the 4-day follow-up period after vaccination. Unsolicited AEs were collected during the 30-day follow-up period after vaccination. SAEs and pIMDs were collected throughout the study period (from Day 1 to Study end (6 months after vaccination)).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RSV OA_Lot 1 | 0/251 (0%) | 8/251 (3.2%) | 181/251 (72.1%) |
| RSV OA_Lot 2 | 2/253 (0.8%) | 6/253 (2.4%) | 192/253 (75.9%) |
| RSV OA_Lot 3 | 2/253 (0.8%) | 7/253 (2.8%) | 195/253 (77.1%) |
| Event | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/251 | 0/253 | 2/253 |
| Atrial fibrillationCardiac disorders | 1/251 | 0/253 | 1/253 |
| Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/251 | 0/253 | 0/253 |
| Metastases to lymph nodesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/251 | 0/253 | 0/253 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/251 | 0/253 | 0/253 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/251 | 0/253 | 0/253 |
| COVID-19Infections and infestations | 1/251 | 0/253 | 0/253 |
| SepsisInfections and infestations | 1/251 | 0/253 | 0/253 |
| Ischaemic strokeNervous system disorders | 1/251 | 0/253 | 0/253 |
| CholecystitisHepatobiliary disorders | 1/251 | 0/253 | 0/253 |
| Event | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 |
|---|---|---|---|
| Injection site painGeneral disorders | 145/251 | 165/253 | 159/253 |
| MyalgiaMusculoskeletal and connective tissue disorders | 78/251 | 87/253 | 86/253 |
| FatigueGeneral disorders | 70/251 | 66/253 | 72/253 |
| HeadacheNervous system disorders | 65/251 | 62/253 | 57/253 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 34/251 | 36/253 | 39/253 |
| Injection site erythemaGeneral disorders | 32/251 | 29/253 | 37/253 |
| Injection site swellingGeneral disorders | 17/251 | 20/253 | 20/253 |
| PyrexiaGeneral disorders | 8/251 | 9/253 | 9/253 |
| NasopharyngitisInfections and infestations | 3/251 | 2/253 | 1/253 |
| Urinary tract infectionInfections and infestations | 3/251 | 0/253 | 0/253 |
| Age, Continuous(Years) | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 | Total |
|---|---|---|---|---|
| Mean | 69.7 ± 6.6 | 70.1 ± 6.6 | 69.9 ± 6.6 | 69.9 ± 6.6 |
| Sex: Female, Male(Participants) | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 | Total |
|---|---|---|---|---|
| Female | 131 | 131 | 109 | 371 |
| Male | 120 | 122 | 144 | 386 |
| Race/Ethnicity, Customized(Participants) | RSV OA_Lot 1 | RSV OA_Lot 2 | RSV OA_Lot 3 | Total |
|---|---|---|---|---|
| ASIAN | 6 | 10 | 10 | 26 |
| BLACK OR AFRICAN AMERICAN | 6 | 3 | 4 | 13 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 1 | 0 | 1 |
| OTHER | 8 | 8 | 6 | 22 |
| WHITE | 231 | 231 | 233 | 695 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Oct 2021 to primary completion in Jan 2022, 3 months.
Results were first posted in Feb 2023, 1 year after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 3 months is below that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →